July 15, 2025

Supplementary Data1 from Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Inhibition using quizartinib and milademetan shows increased efficacy in FLT3-ITD mutant AML, suggesting potential therapeutic benefits.

Synergistic activity of quizartinib and milademetan enhances treatment for FLT3-ITD mutant acute myeloid leukemia.
Inhibition of MDM2 alongside FLT3-ITD targeting demonstrated improved outcomes in lab tests.
Research utilized various cell lines to assess effects of combined drug therapies on cell viability.
Findings could lead to new treatment strategies for patients with FLT3-ITD positive AML, improving survival rates.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark